drugset / Trial / NCT00000505

Thrombolysis in Myocardial Infarction (TIMI)

NCT00000505

RandomizedTreatment

Summary

In TIMI I, to assess the relative thrombolytic activity and side effects of intravenous recombinant tissue-type plasminogen activator (rt-PA) versus intravenous streptokinase in patients with acute myocardial infarction. In TIMI II, to assess whether intravenous rt-PA given in the early hours of acute myocardial infarction should be followed by percutaneous transluminal coronary angioplasty (PTCA).

Timeline

Start
1983-04
Primary completion
Completion
1990-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 80 mg Intravenous
Subject Alteplase Protein / enzyme biologic 100 mg Intravenous
Subject Alteplase Protein / enzyme biologic 150 mg Intravenous